Yes, Alzheimer’s disease is a nervous system disease. Specifically, it is a neurodegenerative disorder of the central nervous system, meaning it progressively destroys nerve cells in the brain. It is the most common form of dementia, contributing to 60 to 70 percent of all dementia cases worldwide, and it follows a distinct biological pattern that separates it from normal brain aging.
How Alzheimer’s Attacks the Nervous System
Alzheimer’s causes damage through two hallmark protein abnormalities in the brain. The first involves fragments of a protein called amyloid-beta, which clump together outside nerve cells to form sticky plaques. These plaques can form rapidly, sometimes within 24 hours, and within a week the surrounding nerve branches begin to swell and deteriorate. Nerve cells near these plaques lose the receptors they need to send signals to each other, which directly undermines learning and memory.
The second involves a protein called tau, which normally helps maintain the internal transport structure of nerve cells. In Alzheimer’s, tau becomes chemically altered and detaches from this scaffolding, causing it to collapse. Without a functioning transport system, neurons essentially starve and die. The loss of connections between nerve cells, called synapses, is one of the strongest predictors of cognitive decline in the disease.
These two processes also trigger a damaging cycle of overstimulation. Nerve cells become chronically activated in a way that floods them with calcium, which suppresses their ability to function and eventually kills them. This process, known as excitotoxicity, accelerates neurodegeneration as the disease progresses.
Which Brain Regions Are Hit First
Alzheimer’s doesn’t strike the entire brain at once. Tau tangles typically appear first in the medial temporal lobe, a region deep in the brain that includes the hippocampus, the structure most critical for forming new memories. This is why early Alzheimer’s almost always shows up as difficulty remembering recent events.
From there, the disease spreads outward. Brain imaging studies have identified seven cortical regions that show the greatest thinning in early Alzheimer’s: the entorhinal cortex, the temporal pole, the lateral temporal cortex, the inferior parietal cortex, the inferior parietal sulcus, the posterior cingulate cortex, and the inferior frontal cortex. These areas handle complex thinking, spatial awareness, language, and the ability to plan.
The pace of damage follows a specific curve. Cortical thinning accelerates during the presymptomatic and early stages, reaching its fastest rate around the point of mild clinical Alzheimer’s. After that, the thinning continues but begins to slow, likely because much of the vulnerable tissue has already been lost. Hippocampal shrinkage, by contrast, keeps accelerating even into moderate and severe stages without a clear peak.
The Brain’s Immune System Backfires
The brain has its own immune cells called microglia. In early Alzheimer’s, microglia recognize amyloid plaques as a threat and attempt to engulf and clear them. This initial response is protective. But as plaque buildup continues, microglia become chronically activated and shift from a protective state to a destructive one.
Overactivated microglia release inflammatory molecules, reactive oxygen species, and other toxic compounds that damage neurons and the cells that insulate nerve fibers. Their ability to clear amyloid diminishes over time, creating a vicious cycle: more plaques trigger more inflammation, which causes more nerve cell death, which releases more debris that further activates microglia. In the later stages of the disease, the destructive form of microglia dominates, and the brain’s capacity to resolve inflammation and repair itself is largely exhausted.
Effects Beyond Memory and Thinking
Because Alzheimer’s is fundamentally a nervous system disease, its reach extends well beyond cognition. The autonomic nervous system, which controls involuntary functions like heart rate, blood pressure, digestion, and bladder control, also sustains progressive damage. Structures involved in autonomic regulation develop neurodegenerative changes that worsen in step with the disease stages first described by neuropathologists Braak and Braak.
This autonomic damage can show up in two ways. Some people develop signs of overactivity, such as high blood pressure, irregular heartbeat, or excessive sweating. Others experience autonomic failure, including dangerously low blood pressure upon standing, slowed digestion, and urinary incontinence. These symptoms are often attributed to aging or other conditions, but in many cases they reflect how deeply Alzheimer’s has infiltrated the nervous system.
How It Differs From Normal Aging
Brains do change with age. Processing speed slows, and occasional forgetfulness is common. But Alzheimer’s is not an inevitable part of getting older. It is a distinct disease with a specific biological signature: the combination of amyloid plaques and tau tangles at levels far beyond what normal aging produces.
The relationship between brain pathology and symptoms is not perfectly straightforward, though. Some people accumulate significant plaques and tangles yet never develop dementia, a phenomenon researchers attribute to “cognitive reserve.” People with higher education or more mentally stimulating lives appear more resistant to cognitive decline even when their brains show substantial Alzheimer’s pathology. Conversely, vascular damage from conditions like high blood pressure or diabetes can produce symptoms that look very similar to Alzheimer’s, and the two often coexist.
How Alzheimer’s Is Diagnosed Today
The diagnostic framework has shifted significantly in recent years. Alzheimer’s is now defined as a biological process that begins while people are still asymptomatic, not a diagnosis that starts only when memory loss becomes obvious. Revised criteria from the Alzheimer’s Association emphasize biological markers over clinical observation alone.
The most important of these are called Core 1 biomarkers, which detect the two signature proteins of the disease. These can be measured through brain imaging that highlights amyloid deposits, through cerebrospinal fluid analysis, or increasingly through blood tests that measure a specific form of tau protein. A single abnormal Core 1 result is now considered sufficient to establish a diagnosis of Alzheimer’s at any point along the disease continuum, from years before symptoms appear through advanced dementia. Additional biomarkers can help predict how quickly someone is likely to decline.
Genetic Risk and the APOE4 Gene
The strongest known genetic risk factor for the common, late-onset form of Alzheimer’s is a variant of the APOE gene called APOE4. Everyone inherits two copies of the APOE gene, and carrying even one APOE4 copy raises risk. But people who inherit two copies face dramatically higher odds: an estimated 60 percent chance of developing Alzheimer’s dementia by age 85. While APOE4 homozygotes make up only about 2 percent of the general population, they account for roughly 15 percent of all Alzheimer’s cases. A 2024 NIH-supported study argued that carrying two APOE4 copies represents a distinct genetic form of the disease rather than simply a risk factor.
Current Treatment Options
For decades, the only available medications managed symptoms without affecting the underlying disease. That changed in 2023 and 2024 with the FDA approval of two antibody-based therapies, lecanemab and donanemab, that target and clear amyloid plaques from the brain. Both are approved for people in early stages, specifically those with mild cognitive impairment or mild dementia who have confirmed amyloid buildup through biomarker testing.
These treatments represent a genuine milestone as the first therapies proven to slow the biological progression of Alzheimer’s. Their effect, however, remains modest. Clinical trials showed they delay cognitive decline by approximately 6 to 12 months in early-stage patients. They do not stop or reverse the disease. For people diagnosed in moderate or advanced stages, these drugs are not currently indicated, and symptom management remains the primary approach.
The Scale of the Problem
Globally, about 57 million people were living with dementia as of 2021, with nearly 10 million new cases each year. Over 60 percent of those affected live in low- and middle-income countries, where access to the newer diagnostic tools and treatments remains limited. Because Alzheimer’s accounts for the majority of dementia cases, it represents one of the largest neurological health burdens worldwide, and one that will grow as populations age.